TRDA - Entrada Therapeutics Inc
IEX Last Trade
17.74
0.240 1.353%
Share volume: 177,913
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$17.50
0.24
1.37%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-07 | 2023-03-06 | 2023-05-10 | 2023-08-08 | 2023-11-07 | 2024-03-13 | 2024-05-07 | |
| Assets | |||||||||
| Total Assets | 295.917 M | 274.463 M | 252.056 M | 475.569 M | 493.983 M | 485.033 M | 469.192 M | 510.844 M | |
| Current Assets | 253.903 M | 234.733 M | 209.875 M | 434.135 M | 390.195 M | 383.043 M | 369.771 M | 414.172 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 9.649 M | 19.161 M | 21.163 M | 16.207 M | 9.662 M | 24.440 M | 11.924 M | 9.244 M | |
| Short Term Investments | 9.649 M | 19.161 M | 21.163 M | 16.207 M | 9.662 M | 24.440 M | 11.924 M | 9.244 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 6.297 M | 3.744 M | 5.025 M | 5.878 M | 77.514 M | |
| Current Cash | 244.254 M | 215.572 M | 188.712 M | 411.631 M | 376.789 M | 353.578 M | 351.969 M | 327.414 M | |
| Total Non-current Assets | 42.014 M | 39.730 M | 42.181 M | 41.434 M | 103.788 M | 101.990 M | 99.421 M | 96.672 M | |
| Property Plant Equipment | 7.785 M | 7.444 M | 7.681 M | 9.394 M | 11.018 M | 11.042 M | 11.191 M | 11.002 M | |
| Other Assets | 30.279 M | 28.336 M | 30.550 M | 28.090 M | 88.820 M | 86.998 M | 84.280 M | 81.720 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 295.917 M | 274.463 M | 252.056 M | 475.569 M | 493.983 M | 485.033 M | 469.192 M | 510.844 M | |
| Total liabilities | 39.878 M | 41.243 M | 39.502 M | 245.957 M | 287.075 M | 238.370 M | 226.832 M | 241.477 M | |
| Total current liabilities | 18.077 M | 21.551 M | 21.972 M | 147.594 M | 125.940 M | 165.433 M | 158.796 M | 173.938 M | |
| Accounts Payable | 4.622 M | 1.341 M | 5.990 M | 6.474 M | 2.422 M | 752.000 K | 3.277 M | 2.527 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 89.241 M | 95.511 M | 10.506 M | 7.715 M | 9.408 M | |
| Current long term debt | 8.114 M | 8.259 M | 8.406 M | 7.103 M | 7.409 M | 6.642 M | 7.909 M | 8.301 M | |
| Long term debt | 21.801 M | 19.692 M | 17.530 M | 9.122 M | 65.624 M | 62.431 M | 60.321 M | 58.131 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 89.241 M | 95.511 M | 10.506 M | 7.715 M | 9.408 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 256.039 M | 233.220 M | 212.554 M | 229.612 M | 206.908 M | 246.663 M | 242.360 M | 269.367 M | |
| Common stock | 31.275 M | 31.298 M | 31.353 M | 32.374 M | 33.163 M | 33.281 M | 33.382 M | 33.497 M | |
| Retained earnings | -138.519 M | -163.656 M | -188.285 M | -194.959 M | -220.887 M | -185.426 M | -194.970 M | -171.474 M |